Biomarker Use in Patients on Active Surveillance

The panel explores the role of biomarkers in monitoring disease progression for prostate cancer patients on active surveillance, discussing how these tests aid in detecting changes that may warrant intervention.

EP: 1.Overview of Prostate Cancer

EP: 2.Challenges of PSA as a Diagnostic Biomarker

EP: 3.Role of Biomarker and Genetic Testing in Prostate Cancer Diagnosis

EP: 4.Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting

EP: 5.High Risk Populations in the Development of Prostate Cancer

EP: 6.Risk Stratification in Prostate Cancer Patients

EP: 7.Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

EP: 8.Influences and Challenges of Biomarkers on Treatment Selection

EP: 9.Efficacy of Biomarker Test Results

Now Viewing

EP: 10.Biomarker Use in Patients on Active Surveillance

EP: 11.Use of Molecular Biomarkers Tests

EP: 12.Integrating Biomarker Testing Into the Patient Care Journey

EP: 13.AI and the Future of Biomarkers in Prostate Cancer

EP: 14.Current Advancements in Biomarker Research

EP: 15.Unmet Needs and Treatment Gaps in Prostate Cancer

EP: 16.Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer

EP: 17.Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing

EP: 18.Tim Richardson, MD, on genetic testing in the era of targeted therapies

EP: 19.Paul Sieber, MD, on the future of genetic testing in prostate cancer

Video content above is prompted by the following question:

• For patients on active surveillance, how do you use biomarkers?

Related Videos

Related Content

Advertisement

December 20th 2024

Investigators identify potential dual targets in prostate cancer

Hannah Clarke

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 16th 2024

High omega-3, low omega-6 diet may slow prostate cancer progression

Hannah Clarke

From baseline to 1 year, the Ki-67 index decreased in the dietary intervention cohort by 15% and increased in the control cohort by 24%.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.

December 9th 2024

FDA grants clearance to NanoKnife System for prostate tissue ablation

Hannah Clarke

The clearance is supported by data from the PRESERVE trial, which evaluated the safety and effectiveness of the NanoKnife System in patients with intermediate-risk prostate cancer.

Related Content

Advertisement

December 20th 2024

Investigators identify potential dual targets in prostate cancer

Hannah Clarke

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 16th 2024

High omega-3, low omega-6 diet may slow prostate cancer progression

Hannah Clarke

From baseline to 1 year, the Ki-67 index decreased in the dietary intervention cohort by 15% and increased in the control cohort by 24%.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.

December 9th 2024

FDA grants clearance to NanoKnife System for prostate tissue ablation

Hannah Clarke

The clearance is supported by data from the PRESERVE trial, which evaluated the safety and effectiveness of the NanoKnife System in patients with intermediate-risk prostate cancer.